Literature DB >> 29446106

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.

T Karlas1, D Petroff1, M Sasso2, J-G Fan3, Y-Q Mi4, V de Lédinghen5, M Kumar6, M Lupsor-Platon7, K-H Han8, A C Cardoso9,10, G Ferraioli11, W-K Chan12, V W-S Wong13, R P Myers14, K Chayama15, M Friedrich-Rust16, M Beaugrand17, F Shen3, J-B Hiriart5, S K Sarin6, R Badea7, H W Lee8, P Marcellin10, C Filice11, S Mahadeva12, G L-H Wong13, P Crotty14, K Masaki15, J Bojunga16, P Bedossa2,17, V Keim1, J Wiegand1.   

Abstract

BACKGROUND: Liver fibrosis is often accompanied by steatosis, particularly in patients with non-alcoholic fatty liver disease (NAFLD), and its non-invasive characterisation is of utmost importance. Vibration-controlled transient elastography is the non-invasive method of choice; however, recent research suggests that steatosis may influence its diagnostic performance. Controlled Attenuation Parameter (CAP) added to transient elastography enables simultaneous assessment of steatosis and fibrosis. AIM: To determine how to use CAP in interpreting liver stiffness measurements.
METHODS: This is a secondary analysis of data from an individual patient data meta-analysis on CAP. The main exclusion criteria for the current analysis were unknown aetiology, unreliable elastography measurement and data already used for the same research question. Aetiology-specific liver stiffness measurement cut-offs were determined and used to estimate positive and negative predictive values (PPV/NPV) with logistic regression as functions of CAP.
RESULTS: Two thousand and fifty eight patients fulfilled the inclusion criteria (37% women, 18% NAFLD/NASH, 42% HBV, 40% HCV, 51% significant fibrosis ≥ F2). Youden optimised cut-offs were only sufficient for ruling out cirrhosis (NPV of 98%). With sensitivity and specificity-optimised cut-offs, NPV for ruling out significant fibrosis was moderate (70%) and could be improved slightly through consideration of CAP. PPV for significant fibrosis and cirrhosis were 68% and 55% respectively, despite specificity-optimised cut-offs for cirrhosis.
CONCLUSIONS: Liver stiffness measurement values below aetiology-specific cut-offs are very useful for ruling out cirrhosis, and to a lesser extent for ruling out significant fibrosis. In the case of the latter, Controlled Attenuation Parameter can improve interpretation slightly. Even if cut-offs are very high, liver stiffness measurements are not very reliable for ruling in fibrosis or cirrhosis.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29446106     DOI: 10.1111/apt.14529

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.

Authors:  Jie Chen; Alina M Allen; Terry M Therneau; Jun Chen; Jiahui Li; Safa Hoodeshenas; Jingbiao Chen; Xin Lu; Zheng Zhu; Sudhakar K Venkatesh; Bin Song; Richard L Ehman; Meng Yin
Journal:  Eur Radiol       Date:  2021-08-25       Impact factor: 5.315

2.  Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.

Authors:  Cynthia Hsu; Cyrielle Caussy; Kento Imajo; Jun Chen; Siddharth Singh; Kellee Kaulback; Minh-Da Le; Jonathan Hooker; Xin Tu; Ricki Bettencourt; Meng Yin; Claude B Sirlin; Richard L Ehman; Atsushi Nakajima; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

3.  Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.

Authors:  Pin-Nan Cheng; Hung-Chih Chiu; Yen-Cheng Chiu; Shu-Chuan Chen; Yi Chen
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

4.  Ultrasonic assessment of liver stiffness and carotid artery elasticity in patients with chronic viral hepatitis.

Authors:  Jing-Hua Li; Ning Zhu; Ying-Bin Min; Xiang-Zhou Shi; Yun-You Duan; Yi-Lin Yang
Journal:  BMC Gastroenterol       Date:  2018-12-05       Impact factor: 3.067

5.  Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease.

Authors:  Matthias Buechter; Sarah Kersting; Guido Gerken; Alisan Kahraman
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

6.  Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.

Authors:  Georg Semmler; Judith Stift; Bernhard Scheiner; Katharina Wöran; Philipp Schwabl; Rafael Paternostro; Theresa Bucsics; Albert Friedrich Stättermayer; Matthias Pinter; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  Dig Dis Sci       Date:  2019-06-17       Impact factor: 3.199

7.  Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

Authors: 
Journal:  Eat Weight Disord       Date:  2021-12-16       Impact factor: 3.008

8.  Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.

Authors:  Núria Fabrellas; Rosario Hernández; Isabel Graupera; Elsa Solà; Pilar Ramos; Natividad Martín; Gemma Sáez; Consuelo Simón; Almudena Pérez; Teresa Graell; Andrea Larrañaga; Manel Garcia; Ana de la Arada; Adrià Juanola; Alicia Coiduras; Isabel Duaso; Angel Casado; Julian Martin; Marta Ginès; Nuria Moreno; Ana Gema Perez; Laia Marti; Mireia Bernat; Montse Sola; Carmina Olivé; Cristina Solé; Pere Ginès
Journal:  PLoS One       Date:  2018-09-18       Impact factor: 3.240

9.  Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study.

Authors:  Xiaofang Zhang; Michelle M J Mens; Yasir J Abozaid; Daniel Bos; Sarwa Darwish Murad; Robert J de Knegt; M Arfan Ikram; Qiuwei Pan; Mohsen Ghanbari
Journal:  Aliment Pharmacol Ther       Date:  2020-11-27       Impact factor: 8.171

Review 10.  Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).

Authors:  Giovanna Ferraioli
Journal:  J Med Ultrason (2001)       Date:  2021-06-16       Impact factor: 1.314

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.